Hair loss treatment and hair regrowth formulations.

Topical tacrolimus suppresses the expression of vascular endothelial growth factor and insulin-like growth factor-1 in late anagen.
Wang Y, Yang S, Wu L, Tu P.

Department of Dermatology and Venerology, Peking University First Hospital, Beijing, China.

Abstract
Tacrolimus has shown promising results in the treatment of various dermatological diseases, including hair loss. The direct effect of tacrolimus on hair follicles and its underlying mechanisms have rarely been investigated. In this study, we investigated the effects of topical tacrolimus on anagen in the hair cycle and on the expression of vascular endothelial growth factor (VEGF) and insulin-like growth factor-1 (IGF-1) mRNAs in mouse skin. Topical tacrolimus 0.1% ointment was applied to one side of the skin of depilated C57BL/6 mice. Skin samples from both sides were taken during the study. Vegf and Igf-1 mRNA were determined by quantitative RT-PCR. No obvious difference in skin colour, hair cycling or histological features was found between the treated and untreated skin, but the levels of Vegf mRNA and Igf-1 mRNA were markedly decreased in the treated skin in late anagen, compared with those in untreated skin.

hair loss treatment and hair regrowth blog

Bimatoprost in the treatment of eyelash hypotrichosis.

Law SK.

edited for hai rloss treatment blog

Eyelashes hypotrichosis is a condition indicated by an inadequate amount of
eyelashes. Hypertrichosis of eyelashes, characterized by excessive eyelash
growth, is a regular phenomenon associated with ophthalmic prostaglandin and
prostamide analogs. Recently, the US Food and Drug Administration approved
Latisse((R)) (bimatoprost 0.03% solution), identical to the ophthalmic solution
for glaucoma treatment, for increasing eyelash length, thickness and darkness in
patients with hypotrichosis of the eyelashes. When prostaglandin and prostamide
analogs interact with the prostanoid receptors in the hair follicle, this most
likely stimulates the resting follicles (telogen phase) to growing follicles
(anagen phase). Prostaglandin and prostamide analogs may also prolong the anagen
phase of eyelashes, leading to an increase of eyelash length. Although
bimatoprost is effective in promoting increased growth of healthy eyelashes and
adnexal hairs, its effectiveness in patients with eyelash with hai rloss due to alopecia areata is debatable and its protective effect is not yet studied in patients with eyelash
loss secondary to radiation or chemotherapy. Bimatoprost is generally safe when
applied to the base of the eyelashes at the lid margin with minimum side effects.
However, other ocular or systemic side effects associated with ophthalmic
prostaglandin and prostamide analogs may occur when instilled on the surface of
the eye, and patients must be informed and monitored.

hair loss treatment regrowth hair loss

Pattern Hair loss and insulin resistance
Nabaie L, ET AL

Edited for Hair regrowth

Hair loss in androgenic alopecia is androgen-dependent. Insulin is found in hair follicles and may play a role in the regulation of androgen metabolism and the hair-regrowth cycle. To compare the insulin resistance between people with androgenic alopecia and a control group. A case-control study was conducted with 97 cases in the patient and 87 in the control group. Serum fasting insulin level, fasting blood glucose, serum total cholesterol, triglyceride and high-density lipoprotein (HDL) were all measured in both groups. There was no difference in serum fasting insulin level, fasting blood glucose, serum total cholesterol, triglyceride, HDL and insulin resistance between the two groups. Despite previous reports suggesting a link, our study found no significant relationship between insulin resistance and androgenic alopecia (hai rloss). Further studies are warranted.